| Hans-Günter Meyer-Thompson | Hepatitiden
EMA. PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2016
At its meeting this week, the Pharmacovigilance Risk Assessment Committee (PRAC) (...) warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C. (EMA, 02.12.2016)